author-photo

Mario Sznol

Yale University
Yale Cancer Center
Vion Pharmaceuticals, Inc.

277

Papers

38263

Citations

Citation Trend

Filter By

Papers (198) Sort By

Journal Conference Others

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases.

2021 American Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Resistance mechanisms to checkpoint inhibitors.

2021 Current Opinion in Immunology
- Sarah A. Weiss
- Mario Sznol
Show All
- Source
- Cite
- Save
Citations (4)
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (1)
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.

2021 Nature
Show All
- Source
- Cite
- Save
Citations (1)
Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

2020 BMJ
Show All
- Source
- Cite
- Save
Citations (1)
A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)